Prediction: Warren Buffett Will Buy These 3 Stocks During His Final 6 Months As Berkshire Hathaway CEO
Buffett will likely buy more of one of his favorite oil stocks -- Occidental Petroleum -- over the next six months.
He could be hungry for a larger position in Domino's Pizza.
The legendary investor also just might authorize more Berkshire Hathaway stock buybacks.
10 stocks we like better than Berkshire Hathaway ›
The end of an era is coming. Warren Buffett will step down as CEO of Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) at the end of 2025 after six decades leading the company. He'll remain Berkshire's chairman, but to say Buffett will be missed is an understatement.
Buffett isn't the kind of person to coast into retirement. You can bet he'll continue to read the annual reports of hundreds of companies throughout the rest of the year. And I suspect the legendary investor will find a few opportunities with his research. I predict that Buffett will buy the following three stocks during his final six months as Berkshire Hathaway CEO.
I'd argue that Occidental Petroleum (NYSE: OXY) has become Buffett's favorite stock over the past few years, except for Berkshire Hathaway itself. Exhibit A is that he has purchased shares of the oil and gas producer a whopping 34 times since the first quarter of 2022.
Buffett wrote to Berkshire Hathaway shareholders in 2024 that Occidental is one of a handful of stocks he expects the conglomerate will "maintain indefinitely." He noted that Berkshire owns warrants that allow it to "materially increase our ownership at a fixed price." Those options expire in a few years, though.
Berkshire currently owns approximately 27% of Occidental, a stake so large that it's the conglomerate's sixth largest holding. However, I think Buffett is itching to buy even more.
In August 2022, Berkshire secured regulatory approval to acquire up to 50% of Occidental. With the prospects of rising oil prices now that the U.S. is involved in Israel's attacks on Iranian nuclear facilities, Occidental could be an attractive target for deploying some of Berkshire's nearly $348 billion cash stockpile.
Buffett has been a net seller of stocks for 10 consecutive quarters. However, that didn't stop him from gobbling up shares of Domino's Pizza (NASDAQ: DPZ) over the past three quarters. I predict the "Oracle of Omaha" is still hungry for more.
Why? For one thing, Domino's Pizza's share price is approaching levels when Berkshire increased its stake in the first quarter of 2025. The price could soon be right for Buffett to buy again.
Importantly, Domino's Pizza checks off a lot of the boxes on Buffett's list for buying a stock. He undoubtedly understands the company's business quite well. Domino's has a strong brand and is a leader in its industry. It's also highly resilient -- a quality that could matter to Buffett even more now than in the past during these turbulent times.
The following chart highlights an incredibly attractive attribute of Domino's Pizza that many stocks can't boast. Its share price has soared over the past 10 years while its valuation, based on the trailing 12-month price-to-earnings ratio, has fallen. Buffett could make a bigger bet that this trend will continue.
You might find this strange, but I'm least confident in my prediction that Buffett will buy more shares of Berkshire Hathaway itself. However, I nonetheless think there's a pretty good chance that he'll authorize some stock buybacks over the next six months.
Berkshire hasn't bought back any of its shares in the last two quarters. Buffett explained in the conglomerate's annual shareholder meeting in May, "If Berkshire buys Berkshire shares in repurchases, we now pay more than you will pay if you buy Berkshire shares." A 1% tax on companies that buy back shares makes it more expensive for Berkshire to repurchase its own stock .
What will it take for Buffett to buy additional Berkshire Hathaway shares? The stock must decline quite a bit. I think this could happen for a couple of reasons.
First, as Buffett's retirement draws closer, some investors could move out of the stock (ill-advisedly, in my opinion). Second, high tariffs could either negatively affect some of Berkshire's businesses or the tariff uncertainty could dissipate, causing investors to find other stocks more attractive. Regardless of how it happens, if Berkshire's share price falls enough, expect the buybacks to resume.
Before you buy stock in Berkshire Hathaway, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Berkshire Hathaway wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!*
Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of June 23, 2025
Keith Speights has positions in Berkshire Hathaway. The Motley Fool has positions in and recommends Berkshire Hathaway and Domino's Pizza. The Motley Fool recommends Occidental Petroleum. The Motley Fool has a disclosure policy.
Prediction: Warren Buffett Will Buy These 3 Stocks During His Final 6 Months As Berkshire Hathaway CEO was originally published by The Motley Fool
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Franklin Resources Stock: Is BEN Underperforming the Financial Sector?
Franklin Resources, Inc. (BEN), headquartered in San Mateo, California, is a global investment management firm serving clients in over 150 countries. Valued at $12 billion by market cap, the company offers a wide range of services across equity, fixed income, alternative investments, and multi-asset strategies, and manages over $1.6 trillion in assets. Companies worth $10 billion or more are generally described as 'large-cap stocks,' and BEN perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the asset management industry. BEN excels through its diverse asset management portfolio, with a balanced mix of equity, fixed-income, and alternative funds, and a global footprint with 30% international assets under management. This diversification provides resilience against regional market fluctuations. BEN's strong brand reputation and trust with investors further drive client retention and attraction. The Next Trillion-Dollar Boom? 3 Stocks to Buy with 300 Million Humanoid Robots on the Horizon. Meta's Mark Zuckerberg Says the Technology They're Developing Will 'See What You See and Hear What You Hear' Warren Buffett's Berkshire Hathaway Now Pays 5% of All Corporate Income Taxes in America Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! Despite its notable strength, BEN slipped 6.1% from its 52-week high of $24.37, achieved on Jul. 18, 2024. Over the past three months, BEN stock gained 15.2%, outperforming the Financial Select Sector SPDR Fund's (XLF) 2.8% gains during the same time frame. In the longer term, shares of BEN rose 12.8% on a YTD basis, outperforming XLF's YTD gains of 5.2%. However, the stock climbed marginally over the past 52 weeks, underperforming XLF's 23% returns over the last year. To confirm the bullish trend, BEN is trading above its 50-day and 200-day moving averages since early May. BEN's weak performance can be linked to substantial outflows from Western Asset Management, a subsidiary facing scrutiny from the SEC over alleged trading misconduct by former co-CIO Ken Leech. On May 2, BEN shares closed up by 7% after reporting its Q2 results. Its adjusted EPS of $0.47 met Wall Street expectations. The company's revenue was $2.1 billion, beating Wall Street forecasts of $2 billion. BEN's rival, State Street Corporation (STT) shares lagged behind the stock, with a 3.2% gain on a YTD basis but outpaced the stock with a 40.1% uptick over the past 52 weeks. Wall Street analysts are cautious on BEN's prospects. The stock has a consensus 'Hold' rating from the 13 analysts covering it. While BEN currently trades above its mean price target of $20.31, the Street-high price target of $28 suggests a 22.3% upside potential. On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
2 Small-Cap Stocks Under $10 to Buy With Big Potential
The biotechnology industry is rapidly changing, thanks to artificial intelligence (AI). In the fast-paced world of biotech investing, small-cap stocks often get overlooked. However, some have the potential to yield significant long-term gains. These emerging biotech companies, each priced under $10, have groundbreaking pipelines. The Next Trillion-Dollar Boom? 3 Stocks to Buy with 300 Million Humanoid Robots on the Horizon. Meta's Mark Zuckerberg Says the Technology They're Developing Will 'See What You See and Hear What You Hear' Warren Buffett's Berkshire Hathaway Now Pays 5% of All Corporate Income Taxes in America Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. For investors willing to embrace some risk for the possibility of outsized returns, these two small-cap biotech stocks could offer significant upside as they race to develop next-generation therapies. Jade Biosciences (JBIO) is a clinical-stage biotechnology company focused on developing innovative therapies for autoimmune diseases with significant unmet needs. Jade (formerly a private biotech) recently completed a merger with Aerovate Therapeutics and will now operate under the name Jade Bioscience. The stock began trading on the Nasdaq Exchange under the symbol JBIO on April 29, 2025. The company's lead candidate is JADE-101, an anti-APRIL monoclonal antibody being developed to treat Immunoglobulin A nephropathy (IgAN), a chronic autoimmune kidney disease that is underdiagnosed but has a high unmet need. The company intends to begin the first-in-human clinical trial in the second half of 2025. It expects interim data in the first half of 2026. The company has also advanced JADE 201 (from the JADE 002 program) and is working on another antibody program, JADE 003. Both are currently in the preclinical development phase. In addition to the merger, Jade secured $300 million in a private placement and converted $95 million in convertible notes to fund its pipeline until at least 2027. At the end of the first quarter, its balance sheet showed cash and cash equivalents totaling $49.9 million. The merger brought in an additional $205 million in proceeds, providing runway through 2027. In Q1, the company spent $20 million on R&D, maintaining its aggressive approach. Jade has a strong capital position right now. Furthermore, if JADE 101 is successful, Jade may have a first-mover advantage in the IgAN treatment market. However, as a clinical-stage biotech company, success may be years away. Thus, Jade is a high-risk, high-reward investment opportunity for those who are willing to take the risk. Overall, Wall Street says JBIO is a 'Strong Buy' with all four analysts in coverage optimistic about the stock. Analysts have set a mean target price of $16.67 for the stock, which implies upside potential of 74% from current levels. Its high price estimate is set at $19, which suggests the stock can go as high as 98% over the next 12 months. With a market cap of $81.5 million, TScan Therapeutics (TCRX) is a clinical-stage biotech company focused on T-cell receptor-engineered T-cell therapies (TCR-T) to treat cancer. TScan stock has dipped 50% year-to-date, compared to the overall market gain of 1.8%. The Phase I ALLOHA trial is evaluating TScan's lead programs, TSC 100 and TSC 101, with the goal of preventing relapse following allogeneic hematopoietic cell transplantation (HCT). The company is planning a registration trial for TSC-101 in the second half of 2025 after receiving feedback from regulators. Additionally, TScan intends to file an investigational new drug (IND) application for TSC-102-A0301. While TScan continues to generate no revenue, its collaboration with Amgen (AMGN) resulted in $2.2 million in net revenue in the first quarter. TScan continues to spend heavily on R&D, which totaled $29.8 million in the quarter. Being in the clinical stage, it reported a net loss of $34.1 million, compared to $30.1 million in the prior-year quarter. On its balance sheet, TScan had $251.7 million in cash, cash equivalents, and marketable securities. The company expects to use this cash balance to fund its operations until the first quarter of 2027. With a strong balance sheet, validated platform, promising dual pipelines, and data releases expected in late 2025, the company has significant potential. It is still a high-risk, high-reward small-cap biotech. For long-term investors, this biotech stock is the one to watch. Overall, Wall Street analysts rate Tscan stock a 'Strong Buy.' Of the eight analysts covering the stock, seven rate it a 'Strong Buy,' while one suggests it is a 'Moderate Buy.' The stock's average analyst target price of $9 suggests upside potential of 525% over the next 12 months. The high price target estimate stands at $12, which suggests the stock can climb as much as 733% from current levels. On the date of publication, Sushree Mohanty did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Cathie Wood Is Dumping Circle Stock. Should You?
Over the past few years, fintech and crypto-related stocks have captured strong investor interest. However, not every high-profile debut turns into a long-term winner. Many stocks have experienced sharp rallies followed by steep pullbacks, making it critical for investors to evaluate each opportunity carefully. Circle (CRCL) made headlines with its June 5 IPO, soaring from its $31 offer price to over $260 within two weeks. As the issuer of the USDC stablecoin, the company showed strong early momentum. But such rapid gains often raise concerns about valuation and sustainability. The Next Trillion-Dollar Boom? 3 Stocks to Buy with 300 Million Humanoid Robots on the Horizon. Meta's Mark Zuckerberg Says the Technology They're Developing Will 'See What You See and Hear What You Hear' Warren Buffett's Berkshire Hathaway Now Pays 5% of All Corporate Income Taxes in America Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Adding to the uncertainty, a surprising move came shortly after the IPO. Cathie Wood's ARK Invest, which had purchased around $373 million worth of Circle stock on day one, trimmed its position by roughly $51.8 million across the Ark Innovation ETF (ARKK), Ark Next Generation Internet ETF (ARKW), and Ark Fintech Innovation ETF (ARKF). The decision suggests even early backers are reassessing the stock's near-term prospects. Still, Circle's ambitions extend beyond its IPO. The company is focused on driving USDC adoption across the digital economy. With regulation evolving and competition rising, risks persist. For those considering CRCL, it's important to look beyond the early hype and weigh its long-term role in shaping digital finance. Founded in 2018, Circle Internet Group is a global fintech firm focused on facilitating international commerce through stablecoins. The company is best known as the issuer of USD Coin, a dollar-backed digital asset used for instant payments, trading, and various DeFi applications. With a $61.5 billion market cap, USDC is a core part of Circle's mission to bridge digital and traditional finance. Since its IPO, Circle's market cap has soared by over 700%, rising to over $50 billion. Following its sharp rally, CRCL now trades at a premium valuation. Its adjusted forward price-earnings ratio of 198x is nearly 800% higher than the sector median of 22x, while its price-sales ratio of 20.4x far exceeds the industry average of 2.9x. These stretched multiples suggest the stock is priced for perfection, leaving little room for error and highlighting the need for cautious expectations moving forward. Circle priced its IPO at $31 on June 5, 2025, implying a near $7 billion valuation and drawing heavy demand that led to significant oversubscription. On debut day, ARK Invest snapped up roughly $373 million of shares, pushing CRCL sharply above the offer price. Market enthusiasm received a further boost when the U.S. Senate passed the GENIUS Act, which aims to establish clear federal guardrails for stablecoins, including full-reserve backing and regular audits. This regulatory clarity is crucial for Circle, as it reduces uncertainty and paves the way for broader institutional adoption of USDC in payments and cross-border settlements. By defining compliance standards, the bill aims to strengthen confidence in stablecoins and supports Circle's ambitions to integrate digital dollars with traditional finance. Overall, the IPO's strong reception combined with supportive legislation sets a firmer foundation for Circle's long-term growth. Circle has strong financial health, with solid revenue growth but relatively thin profits. In Q1 2025, the company posted $579 million in revenue and roughly $65 million in net income. Its balance sheet remains solid, with $1.9 billion in cash. Most of Circle's income is generated from interest on USDC reserves, but profit margins are pressured by high distribution costs. Coinbase (COIN) receives nearly half of Circle's USDC reserve income. In 2024, Circle paid approximately $908 million to Coinbase, with total distribution expenses exceeding $1 billion, significantly eating into yield. Despite this, the company reported $122 million in adjusted EBITDA for Q1, translating to an 11% net profit margin, which is modest for a high-growth fintech. If Circle can renegotiate distribution terms, particularly with Coinbase, profitability could improve meaningfully. Only one Wall Street analyst tracked by Barchart is currently covering Circle and issued a 'Strong Buy' rating, though no official price target has been set yet. This limited coverage reflects how new the stock is to public markets, but early sentiment remains positive. Despite its high valuation and Cathie Wood's recent partial exit, Circle's long-term prospects appear strong. Regulatory clarity, driven by the GENIUS Act, is giving stablecoins like USDC a more credible role in the financial system. With rising USDC adoption and a growing presence in cross-border payments, Circle is well-positioned for further upside. On the date of publication, Nauman Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
